bluebird bio (NASDAQ:BLUE) Price Target Cut to $4.00 by Analysts at Barclays

bluebird bio (NASDAQ:BLUE) had its price objective cut by Barclays from $8.00 to $4.00 in a report released on Thursday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Other equities analysts have also recently issued research reports about the company. Robert W. Baird dropped their price objective on bluebird bio from $7.00 to $6.00 and set an outperform rating for the company in a report on Thursday. JPMorgan Chase & Co. cut shares of bluebird bio from an overweight rating to a neutral rating in a report on Thursday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and an average target price of $4.74.

bluebird bio Trading Up 0.5 %

Shares of NASDAQ:BLUE opened at $0.71 on Thursday. bluebird bio has a 12 month low of $0.68 and a 12 month high of $5.53. The company has a market capitalization of $77.53 million, a price-to-earnings ratio of -0.96 and a beta of 0.81. The firm’s 50-day moving average is $1.02 and its 200 day moving average is $1.09.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allegheny Financial Group LTD bought a new stake in shares of bluebird bio in the 2nd quarter valued at about $25,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of bluebird bio during the 4th quarter valued at $37,000. Sequoia Financial Advisors LLC acquired a new stake in bluebird bio in the fourth quarter worth about $37,000. Johnson Investment Counsel Inc. lifted its position in bluebird bio by 111.1% during the 4th quarter. Johnson Investment Counsel Inc. now owns 27,889 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 14,680 shares during the period. Finally, Enterprise Bank & Trust Co purchased a new stake in bluebird bio during the 1st quarter valued at about $38,000. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.